Prelude Capital Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Prelude Capital Management’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-14,581	Closed	-$4.62M	–	1577
2023 Q4	$4.62M	Buy	+14,581	New	+$2.83M	0.31%	60
2023 Q2	–	Sell	-1,726	Closed	-$314K	–	1426
2023 Q1	$314K	Buy	+1,726	New	+$330K	0.02%	629
2022 Q4	–	Sell	-1,514	Closed	-$341K	–	1710
2022 Q3	$341K	Buy	+1,514	New	+$306K	0.01%	814

Other funds holding KRTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Prelude Capital Management's KRTX Position: Q1 2024 in Review

Prelude Capital Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 14,581 shares — an estimated $4.62M sold.

Prelude Capital Management first reported a position in KRTX in Q3 2022 and held it in 3 quarters. The position peaked at $4.62M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

Prelude Capital Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Prelude Capital Management sold 14,581 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $4.62M.
Prelude Capital Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
Prelude Capital Management's Karuna Therapeutics, Inc. Common Stock position peaked at $4.62M in Q4 2023.
2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Prelude Capital Management's 13F filing for Q1 2024, filed 15 May 2024.